Global Lymphoma Drugs Market 2017-2021: Key Regions and Forecasts by Technavio

Technavio has published a new report on the global lymphoma drugs market from 2017-2021. (Graphic: Business Wire)

???pagination.previous??? ???pagination.next???

LONDON--()--The global lymphoma drugs market is expected to grow at a CAGR of around 8% during the forecast period, according to Technavio’s latest market research.

In this market research report, Technavio covers the market outlook and growth prospects of the global lymphoma drugs market for 2017-2021. The market is further categorized into two major segments based on disease type which include Hodgkin lymphoma (HL) drugs and non-Hodgkin lymphoma (NHL) drugs. The NHL drugs accounted for more than 92% of the market share in 2016.

“Cancer is a huge burden for the society across the globe. The rising cases of lymphoma are one of the major factors driving the global lymphoma drugs market. Developed countries such as the US, Australia, Japan, and those of European countries such as the UK, Italy, France, Germany, and Spain are expected to witness a higher rate of the disease and hence will contribute to the higher growth rate of the market,” says Sapna Jha, a lead research analyst for oncology at Technavio.

Technavio’s research analysts segment the global lymphoma drugs market into the following regions:

  • Americas
  • EMEA
  • APAC

Lymphoma drugs market in Americas

The Americas dominated the global lymphoma drugs market, accounting for almost 49% of the global revenue in 2016. The US is the largest revenue contributor, capturing a significant portion of the market. The growing number of lymphoma patients in the US is expected to be one of the major growth factors for the region.

Apart from the US, Canada also has a relatively high prevalence rate of lymphoma especially NHL. During the past few years, lymphoma has been the most common form of cancer in children in Canada after leukemia and cancers of the central nervous system (CNS). However, better treatment facilities for lymphoma has declined the overall mortality rate to about 2% since 2001. The introduction of highly active antiretroviral therapy (HAART) has led to the downfall of aggressive forms of NHL, which are also attributed to the HIV infections.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Lymphoma drugs market in EMEA

The lymphoma drugs market in EMEA is expected to grow at a high CAGR of 8% during the forecast period. High prevalence rate of the disease in some of the European countries such as the UK, France, Italy, Germany, and Spain and some of the African countries will lead to higher demand for the drugs in the region. Lymphoma is the third most common cancer type affecting children in the UK and accounts for around 10% of the total cancer cases in the country.

“Industry-academia collaborations assist global healthcare organizations to achieve their drug-related global goals, which will also help to drive the market during the forecast period. For instance, organizations such as World Health Organization, the United Nations Children's Emergency Fund, and Gavi support and conduct various awareness programs to educate end-users about the treatment options available for lymphoma,” says Sapna.

Lymphoma drugs market in APAC

The APAC region is mainly driven by the high prevalence of the disease in countries such as Australia and Japan. Australia and New Zealand are among the countries with the highest incident rate of NHL on a global basis. It is the sixth most common type of cancer in the country. However, improving treatment facilities have led to high survival rate against the disease in the country. For instance, the country has had an average survival rate of above 75% over the last five years.

The top vendors in the global lymphoma drugs market as highlighted in this market research analysis are:

  • Celgene
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Seattle Genetics

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like medical imaging, cardiovascular devices, and vaccines. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

The global lymphoma drugs market is expected to grow at a CAGR of around 8% during the forecast period, 2017-2021.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com